#USA #London #OncoBayes #OB-001 #ADC resistance

OncoBayes Makes Significant Progress with OB-001

OncoBayes, a clinical-stage pharmaceutical company, recently declared the successful conclusion of preclinical trials for its exciting drug candidate, OB-001. This breakthrough addresses critical challenges in oncology, particularly those associated with antibody-drug conjugate (ADC) resistance and brain penetration of tyrosine kinase inhibitors (TKIs).

OB-001 is notable for its selective inhibition of two crucial efflux pumps, P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). These pumps are found both on the blood-brain barrier and within tumor cells, which are notorious for hindering drug effectiveness. As a result, OB-001 is being formulated as a once-daily oral tablet designed to enhance the efficacy of existing oncology therapies.

In recent studies conducted on perfused-brain mice, OB-001 pretreatment led to a remarkable increase in the brain exposure of several leading TKIs while leaving systemic (plasma) exposure relatively unchanged. Notably, data presented at the 2026 AACR conference indicated that OB-001 could increase brain levels of osimertinib by nearly 400% without significant systemic alterations. Such an enhancement promises to lead to substantial improvements in progression-free survival among patients with EGFR-mutated non-small cell lung cancer (NSCLC) and may also benefit those suffering from breast cancer with brain metastases.

The same efflux pumps targeted by OB-001 have been recognized as significant contributors to ADC resistance. Overexpression of these pumps results in diminished drug concentrations within tumors, posing a major hurdle for effective treatment. Preclinical evaluations utilizing a bidirectional transporter assay demonstrated OB-001's capacity to reduce efflux for several prominent payloads, including SN-38 (associated with Trodelvy®), DM4 (linked to Elahere®), and DXd (related to Enhertu®).

With the groundwork laid, OncoBayes is preparing to embark on a clinical trial program aimed at generating proof-of-concept (POC) data for OB-001 in conjunction with osimertinib. The company also plans to assess its potential for re-sensitizing resistant tumors to T-DXd therapies.

Jim Millen, the CEO of OncoBayes, expressed optimism about this breakthrough, stating, “This is a critical milestone for our team, and we are now well positioned to initiate our clinical plans with OB-001. This drug is on track to become a first-in-class therapy with broad potential as a straightforward oral addition to numerous blockbuster oncology treatments.” Millen emphasized the potential of OB-001 to redefine treatment strategies, summarizing it as a “pipeline in a product opportunity.”

As the world watches OncoBayes’s progress, the implications of OB-001 could reshape the treatment landscape for cancer patients, particularly those facing the daunting challenges of ADC resistance and brain metastases. The data thus far is promising, but clinical trials will be crucial in determining how effectively OB-001 can fulfill this potential. As OncoBayes moves forward, it stands at the forefront of innovative cancer treatments, aiming to provide new hope for patients battling these complex diseases.